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Introduction
Immune reconstitution after allogeneic hematopoietic stem cell transplantation (alloHSCT) is a complex process consisting of various components of the innate and adaptive immune system (1, 2) . While early reconstitution is mainly characterized by restoration of mucosal barriers, neutrophil recovery and NK-cell recovery, reconstitution in the later post-transplant period is dominated by recovery of newly developed T cells. Two main pathways of T-cell regeneration contribute to post-transplant T-cell recovery: thymopoiesis and peripheral expansion of mature T cells (3, 4) . Thymopoiesis provides a de novo pool of naïve T cells that is essential for diverse T-cell receptor (TCR) repertoire formation and sustained long-term immunity. It has been shown that recovery of thymopoiesis after alloHSCT is compromised in older patients, in recipients with reduced pre-transplant thymic function, and in patients suffering from acute and chronic graft-versus-host disease (GvHD) (5) (6) (7) (8) (9) (10) (11) (12) (13) . However, it is unclear to what extent absent recovery of thymopoiesis itself predicts for subsequent opportunistic infections and overall non-relapse mortality. Therefore, we set out to prospectively monitor recovery of thymopoiesis following alloHSCT, record all postengraftment opportunistic infections during follow-up, and address the question if and to what extent patients without sufficient thymic recovery would be at higher risk for subsequent infections and adverse outcome.
Design and methods

Patients and grafts
Eighty-three patients receiving a myeloablative alloHSCT at the Erasmus MC/Daniel den Hoed Cancer Center from either a matched related (MRD; n=50) or unrelated donor (n=33) were included in this study. HLA-typing included high-resolution typing for HLA-A, B, C, DRB1, DQB1 and DPB1. Patients and donors were considered matched if an 8/8 match for A,B,C, DRB1 at the allele level was obtained and 27 (82%) unrelated donor-recipient pairs were thereby considered allele-matched. (Table 1) . Patients were considered "standard risk" in case of a diagnosis of acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission, chronic myeloid leukemia in first chronic phase, and untreated aplastic anemia. All other diagnoses were considered "high risk." The institutional review board approved the protocols and all patients and donors provided informed consent. Bone marrow or mobilized peripheral blood progenitor cells were harvested as described (14) . T-cell depletion was performed predominantly by selection of CD34 + . CD34 + cells were positively selected using an immunoadsorption biotin-avidin column (Ceprate SCsystem; CellPro, Bothell, WA, USA) or by immunomagnetic cell selection using the CliniMACS system (CliniMACS, Miltenyi Biotec, Bergisch Gladbach, Germany). If the CD34 + -selection procedure resulted in less than 1 × 10 5 CD3 + T cells/kg, then the graft was supplemented to contain an intended minimum of 1-2 × 10 5 CD3 + T cells/kg (15) . Transplantations were performed between January 1998 and December 2001.
Conditioning and supportive care
Conditioning and GvHD profylaxis were performed as described previously (15) . All patients received prophylactic ciprofloxacin (500 mg orally twice daily) and prophylactic fluconazole (200 mg once daily) as infection prevention until neutrophil recovery. Trimethoprimsulfamethoxazol (480 mg once daily) was administered for the prevention of infections with
Pneumocystis carinii from neutrophil recovery (> 0.5 × 10 9 /L) until at least 6 months after transplantation or prolonged in case of chronic GvHD (cGvHD). All patients received prophylactic acyclovir from transplantation until cessation of cyclosporin. GvHD was graded and treated as described previously (15) .
Infections
All infections diagnosed following transplantation were evaluated and scored by grade, localization, and causative microorganism of infection according to the NCI common toxicity criteria (CTC) as described previously (15 or indirectly (e.g., sepsis with subsequent adult respiratory distress syndrome). CMV and EBV reactivation were diagnosed and treated as described previously (15) .
Immune monitoring
ALC. Peripheral blood absolute lymphocyte counts (ALC; 10 9 /liter blood) were calculated using the clinical laboratory leukocyte count and percentage of lymphocytes (leukocyte count × % lymphocytes) at months 1, 2, 3, 6, 9, 12, 18 and 24 months following transplantation. the assumption that the total number of nucleated cells in the peripheral blood is represented by the CD45 + cell subset. The ratio of CD45/CD3 cells in PBMC's was determined by flow cytometry. The frequency of peripheral blood sjTRECs is not only influenced by thymic output, but also by post-rearrangement expansion (9) . SjTREC content (sjTREC/ml blood) is not influenced by peripheral expansion and may therefore be a better estimate of thymic output (18) . sjTREC content (sjTREC/ml blood) was calculated by multiplying the sjTREC frequency (sjTREC/10 5 CD3 + T cells) with the absolute numbers of CD3 + T cells/ml blood.
Lymphocyte subsets
Statistical considerations
Endpoints of the study included hematological recovery, acute GvHD (aGvHD) grades 2-4, Causes of death were classified as relapse-related mortality or NRM, and these were considered competing risks. Distribution of EBMT risk score, taking age, stage of disease, donor type, gender and time to transplantation into account, was performed as described (19) and presented as categories with 0-2, 3, 4 and 5-7. Overall survival was calculated using the actuarial method of Kaplan and Meier, and a Kaplan-Meier curve was generated to illustrate 9 survival. For all other time-to-event endpoints, cumulative incidences were calculated taking into account the competing risks, and cumulative incidence curves were generated. Univariate and multivariate Cox regression analyses were performed to evaluate the impact of lymphocyte (subset) recovery and sjTREC content or frequency at 2, 6, 9 and 12 months on clinical outcome beyond those time points. Hazard ratios (HRs) and corresponding 95%
confidence intervals (CIs) were determined, and p-values were calculated using the likelihood ratio test. Patients who were considered a failure due to the competing risks were censored in the Cox regression analyses. The immunological and sjTREC data at those time points were also compared to 22 healthy donors, using the Wilcoxon rank-sum test. All reported p values are two-sided, and a significance level α = 0.05 was used.
Results
Patient characteristics are presented in were reported between 2 and 4 years after transplantation (rate: 0.01 infections/100 patientdays). One or more causative microorganisms were identified in 69% of reported infections.
The most important infectious agents were viruses followed by bacteria and fungi (data not shown). The cumulative incidence of severe infections (either CTC grade 3 and/or 4) was comparable between recipients that did or did not receive ATG as part of the conditioning regimen.
Immune recovery
Neutrophil recovery (absolute neutrophil count > 0. Patients who failed to recover sjTREC + T cells (defined as absent sjTREC + T cells in blood), however, were at significantly higher risk for a severe infection as compared to patients who did show sjTREC + T cell recovery as depicted in Figure 3 . In multivariable analysis, the predictive impact of sjTREC + cell recovery was estimated and weighed against the risk factors age, risk-status and type of donor, as the latter 3 parameters were associated with OS in univariate analysis. Results are presented in Table 2 . A more than 3-fold lower risk of (Table 2 ) with hazard ratio's below 0.1 (p<0.01).
Lastly, the predictive impact of sjTREC + T-cell recovery on OS was assessed. Both risk-status and sjTREC + T-cell recovery impacted on subsequent OS (Table 2 ) taking the 6 month assessment into account, whereas sjTREC + T-cell recovery at 12 month did not predict for subsequent overall survival. The overall lymphocyte count as well as the various lymphocyte subsets did not predict for OS in multivariate analysis (data not shown).
Discussion
Recovery of thymopoiesis after alloHSCT may be severely protracted and plays an important In addition, given the adverse effect of high-dose radiotherapy (22, 23) on thymic epithelium, both the myeloablative conditioning regimen and T-cell depletion strategy may have acted in concert by impairing thymopoiesis without providing compensation by peripheral donor Tcell recovery.
Thymopoiesis is a fine-tuned selection process of thymocytes resulting in production of naïve T cells with a broad TCR repertoire that selectively recognize non-self antigens and allow the development of an adequate immune response to a broad range of infectious pathogens (24) .
Thymopoiesis in healthy humans gradually declines with age although the ability to generate new naïve T cells is preserved in adulthood (25) . Immune reconstitution and especially restoration of the TCR repertoire in the later post-transplant period is a protracted process, which usually takes many months or years to be completed (2, 4, 26), as was evident in our study of older high-risk alloHSCT recipients. Regeneration of a broad and functionally competent TCR repertoire after alloHSCT requires an intact thymic function, that is compromised however by pre-transplant conditioning, by an age-related involution of the thymus, and by the donor-derived allo-reactive immune response to recipient tissues (5-10, Retrospectively, we did not find an association between acute GvHD and impaired thymopoiesis, but more patients failing to recover at 12 months had a history of extensive chronic GVHD, that had occurred during the first year post-transplant. Several clinical and experimental studies have highlighted that GvHD does severely impair thymopoiesis, although recapitulation of thymic function after a history of acute GvHD is still possible (6, 10, 12, 13, 21, 24) . While it has been difficult to dissect the adverse effects of immunosuppressive drugs and GvHD itself in clinical studies, experimental studies have suggested that epithelial destruction rather than the apoptotic effects of corticosteroids may account for thymic lymphoid depletion (24) . Therefore, preservation of the thymic epithelium by new therapeutic approaches has lately received more attention (27) (28) (29) .
We measured thymic function by both the frequency of sjTREC + T cells and the sjTREC content per mL peripheral blood. The latter estimate was added in order to correct for peripheral homeostatic T-cell expansion, which may result in dilution of sjTRECs and subsequent underestimation of thymic function (18) . However, sjTREC frequencies and contents measured in the present study were highly correlated and the predictive impact of either estimate did not differ, as observed previously (13 EBMT-risk score (19) . The HCT-CI score selectively takes the number of co-morbidities into account and has been validated prospectively in a number of centers and transplant modalities (32, 33) . The EBMT risk score is based on five criteria, including disease stage, patient age, donor type, time interval from diagnosis to transplantation, and donor-recipient sex combination (19) . That score was validated in several independent patient cohorts, confirmed over time, and recently also validated in acute leukemia patients (34) . Also in the current umbilical cord blood (UCB). Especially, the increased use of UCB in adult patients and nonmyeloablative conditioning in aged patients may be associated with a failure to recover thymopoiesis and late NRM (21, 54, 55) .
In conclusion, failure to recover thymopoiesis after myeloablative T-cell depleted alloHSCT puts recipients at high risk of developing opportunistic infections of either bacterial, fungal, or viral origin. Despite effective prophylactic measures, such infections translate into increased NRM and adverse outcome after alloHSCT, highlighting the need to preserve or regenerate thymic function and more specifically, the restoration of the thymic epithelium that supports and directs thymopoiesis.
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